article

Calcilytics as potential novel therapeutic treatments to halt Alzheimer’s disease

Alzheimer’s disease (AD) is the most prevalent form of dementia.1 The common (>95% of cases) slow-developing form of the ailment is known as late-onset AD (LOAD) or sporadic AD (SAD). The rare (<5% of cases), faster-developing form of the disease is early-onset AD (EOAD) or familial AD (FAD), the symptoms of which manifest at an unusually early age (under 60). These patients carry a mutant gene for the β-secretase 1 (BACE1), or more often the presenilin (PSEN1 or PSEN2), components of the γ-secretase complex causing the overproduction of amyloid-β42 oligomers (Aβ42-os).2

Alzheimer's

The rest of this article is restricted to logged-in members. Login or subscribe free to read it.


Send this to a friend